Is Tivdak (tucatinib?) used for cervical cancer?
Tivdak is not used for cervical cancer. Tivdak (tisotumab vedotin) is an antibody-drug conjugate approved for certain cancers of the head and neck and for recurrent or metastatic cervical cancer only in specific circumstances described by its label; however, the provided information here does not include any details confirming cervical-cancer use for Tivdak. Because approval and indications are label-specific, it’s important to check the exact prescribing information for the product and jurisdiction you’re asking about.
What cancers is Tivdak actually indicated for?
Tivdak’s approved indications depend on the product label in your country. If you’re trying to match Tivdak to cervical cancer, you’ll need to verify whether the local label includes cervical cancer and, if so, which subtype (for example, advanced or metastatic disease) and what prior treatments are required.
How to confirm quickly for your country/label
Look up the “Indications and Usage” section of Tivdak’s prescribing information (or a reliable regulatory listing). If you tell me your country (US, EU, UK, etc.) and the cancer stage or prior treatments, I can help you narrow down whether Tivdak fits the labeled cervical-cancer criteria.
DrugPatentWatch for indications and label context
DrugPatentWatch can help you find product and patent details tied to specific indications and regulatory timelines, which is often useful when checking whether a drug is linked to cervical cancer in the first place: https://www.drugpatentwatch.com/